HK1062836A1 - Nucleic acid vaccines for prevention of flavivirusinfection - Google Patents
Nucleic acid vaccines for prevention of flavivirusinfectionInfo
- Publication number
- HK1062836A1 HK1062836A1 HK04105654A HK04105654A HK1062836A1 HK 1062836 A1 HK1062836 A1 HK 1062836A1 HK 04105654 A HK04105654 A HK 04105654A HK 04105654 A HK04105654 A HK 04105654A HK 1062836 A1 HK1062836 A1 HK 1062836A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- flavivirusinfection
- prevention
- nucleic acid
- acid vaccines
- vaccines
- Prior art date
Links
- 206010054261 Flavivirus infection Diseases 0.000 title 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title 1
- 229940023146 nucleic acid vaccine Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/826,115 US7227011B2 (en) | 1998-06-04 | 2001-04-04 | Nucleic acid vaccines for prevention of flavivirus infection |
PCT/US2002/010764 WO2002081754A1 (fr) | 2001-04-04 | 2002-04-04 | Vaccins d'acide nucleique pour la prevention d'infection a flavivirus |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1062836A1 true HK1062836A1 (en) | 2004-11-26 |
Family
ID=25245753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04105654A HK1062836A1 (en) | 2001-04-04 | 2004-08-02 | Nucleic acid vaccines for prevention of flavivirusinfection |
Country Status (12)
Country | Link |
---|---|
US (6) | US7227011B2 (fr) |
EP (3) | EP1383931A4 (fr) |
JP (2) | JP4448281B2 (fr) |
KR (1) | KR100913984B1 (fr) |
CN (2) | CN1304575C (fr) |
BR (1) | BRPI0208301B8 (fr) |
CA (1) | CA2443323C (fr) |
HK (1) | HK1062836A1 (fr) |
MX (1) | MXPA03008838A (fr) |
NZ (1) | NZ529106A (fr) |
WO (1) | WO2002081754A1 (fr) |
ZA (1) | ZA200307580B (fr) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
ATE378348T1 (de) | 2000-01-14 | 2007-11-15 | Us Health | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
FR2823222B1 (fr) * | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
US20050031641A1 (en) * | 2001-04-06 | 2005-02-10 | Loosmore Sheena May | Recombinant vaccine against West Nile Virus |
US7740863B2 (en) * | 2001-04-06 | 2010-06-22 | Merial | Recombinant vaccine against West Nile Virus |
US20040037848A1 (en) * | 2001-04-06 | 2004-02-26 | Audonnet Jean-Christophe Francis | Recombinant vaccine against West Nile Virus |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
MXPA04000680A (es) * | 2001-07-27 | 2004-04-05 | Wyeth Corp | Vacuna para virus west nile. |
AU2002361468A1 (en) * | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
US7351547B2 (en) * | 2002-10-31 | 2008-04-01 | Health Research, Inc. | Diagnostic test for West Nile virus |
AU2003263853A1 (en) * | 2002-08-16 | 2004-03-03 | Board Of Regents The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain iii antigens |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
JP5250179B2 (ja) * | 2002-11-08 | 2013-07-31 | ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド | フラビウイルス融合インヒビター |
CA2432738A1 (fr) * | 2003-02-26 | 2004-08-26 | Philippe Despres | Nouvelles proteines des virus de la dengue et du nil et genes codant pour ces proteines, et leurs utilisations dans des vaccins et dans des applications therapeutiques et diagnostiques |
US8475808B2 (en) | 2003-05-23 | 2013-07-02 | Novartis Vaccines And Diagnostics, Inc. | Immunogenic reagents from west nile virus |
US7060280B2 (en) * | 2003-06-11 | 2006-06-13 | Academia Sinica | Immunization against flavivirus |
US7585621B2 (en) | 2003-09-09 | 2009-09-08 | Idexx Laboratories, Inc. | Detection of West Nile virus infection and vaccination |
US7074555B2 (en) | 2004-04-28 | 2006-07-11 | Idexx Laboratories, Inc. | Detection of West Nile Virus |
EP1742963A2 (fr) * | 2004-05-04 | 2007-01-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Synthese et purification de particules de type viral de virus du nil occidental |
CN103088038B (zh) * | 2004-07-12 | 2015-06-24 | 美国天甲生物医药有限公司 | 黄病毒疫苗 |
EP1784487B1 (fr) | 2004-07-27 | 2011-08-24 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Localisationd'epitopes d'enveloppe a reactivite croisee de la glycoproteine du flavivirus |
US7482017B2 (en) * | 2004-09-09 | 2009-01-27 | Research Development Foundation | Flavivirus variants having phenotypic variation and immunogenic compositions thereof |
WO2006044857A2 (fr) * | 2004-10-20 | 2006-04-27 | Acambis Inc. | Vaccins contre le virus de l'encephalite japonaise et le virus du nil occidental |
AU2006232865A1 (en) * | 2005-04-01 | 2006-10-12 | Wyeth | Use of WNV DNA vaccine in combination with a conventional vaccine to overcome immunogen interference |
KR101730748B1 (ko) | 2005-04-08 | 2017-04-26 | 와이어쓰 엘엘씨 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
CN101222936A (zh) | 2005-06-24 | 2008-07-16 | 英特威国际有限公司 | 灭活的嵌合疫苗和相关的使用方法 |
US7455842B2 (en) * | 2005-12-05 | 2008-11-25 | University Of Kansas | Chimeric West Nile viruses and uses thereof |
US20070190617A1 (en) * | 2006-02-13 | 2007-08-16 | Chang-Jer Wu | DNA vaccine for Japanese encephalitis virus |
US20080044808A1 (en) * | 2006-08-15 | 2008-02-21 | Qian-Li Song | West nile virus antigen and assay |
US8241638B2 (en) * | 2006-11-09 | 2012-08-14 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using the prime-boost approach |
PL2308514T3 (pl) | 2007-03-23 | 2013-11-29 | To Bbb Holding B V | Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg |
JP2008263964A (ja) * | 2007-03-29 | 2008-11-06 | Yamaguchi Univ | コウモリ由来細胞株 |
EP2003144A1 (fr) * | 2007-06-15 | 2008-12-17 | Institut Pasteur | Procédé de diagnostic ou de dépistage d'une arbovirose, réactifs utiles dans ledit procédé et leurs applications |
WO2009024534A2 (fr) * | 2007-08-17 | 2009-02-26 | Intercell Ag | Virus de l'encéphalite japonaise (jev) et peptides du virus de l'encéphalite de la taïga (tbev) stimulant des réponses de lymphocytes t humains |
US8138318B2 (en) * | 2007-09-13 | 2012-03-20 | Abbott Laboratories | Hepatitis B pre-S2 nucleic acid |
MX2010007461A (es) * | 2008-01-11 | 2010-10-20 | VGX Pharmaceuticals LLC | Nuevas vacunas contra multiples subtipos del virus del dengue. |
JP2011510672A (ja) * | 2008-02-08 | 2011-04-07 | インターツェル・アクチェンゲゼルシャフト | ワクチンとして使用するための、カプシドタンパク質中に欠失を含むフラビウイルス科突然変異体 |
MX2010011373A (es) * | 2008-04-22 | 2010-11-12 | Cytos Biotechnology Ag | Composiciones de vacuna para el tratamiento de la fiebre del dengue y uso de las mismas. |
CN101333246B (zh) * | 2008-07-30 | 2011-04-13 | 中国农业科学院哈尔滨兽医研究所 | 乙型脑炎病毒e蛋白中和性b细胞抗原表位多肽及其应用 |
NZ603854A (en) | 2008-08-29 | 2015-03-27 | Boehringer Ingelheim Vetmed | West nile virus vaccine |
CN101607983B (zh) * | 2009-07-29 | 2012-06-13 | 中国农业科学院哈尔滨兽医研究所 | 乙型脑炎病毒PrM/M蛋白B细胞抗原表位多肽及应用 |
ES2524975T3 (es) | 2009-07-31 | 2014-12-16 | Ge Healthcare Bio-Sciences Corp. | Cepa del virus de la fiebre amarilla de alto rendimiento con mayor propagación en células |
US20110182976A1 (en) * | 2010-01-28 | 2011-07-28 | National Taiwan Ocean University | Lipoplex-patch based dna vaccine |
US8993744B2 (en) | 2010-05-21 | 2015-03-31 | University of Pittsburgh—of the Commonwealth System of Higher Education | Universal dengue virus sequences and methods of use |
AR079970A1 (es) * | 2010-07-23 | 2012-02-29 | Xcellerex Inc | Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas |
WO2012065105A2 (fr) * | 2010-11-12 | 2012-05-18 | Thomas Monath | Vaccins contre des flavivirus chimériques |
CA2829226C (fr) | 2011-03-14 | 2023-01-03 | Boehringer Ingelheim Vetmedica, Inc. | Vaccin contre la rhinite equine |
WO2013059493A1 (fr) | 2011-10-20 | 2013-04-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Polypeptides d'e-glycoprotéine du virus de la dengue contenant des mutations qui éliminent des épitopes immunodominants à réaction croisée |
US8920804B2 (en) | 2011-12-22 | 2014-12-30 | Inbios International, Inc. | Methods and materials for the detection of dengue virus infection |
WO2014016362A1 (fr) * | 2012-07-24 | 2014-01-30 | Sanofi Pasteur | Compositions de vaccin pour prévenir une infection provoquée par le virus de la dengue |
TW201620546A (zh) | 2014-09-02 | 2016-06-16 | 賽諾菲巴斯德公司 | 疫苗組合物 |
EP3031923A1 (fr) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux |
CN104630160B (zh) * | 2015-01-23 | 2018-04-27 | 中国农业科学院哈尔滨兽医研究所 | 表达西尼罗热病毒PrM/E蛋白的重组新城疫LaSota疫苗株 |
BR112017028212A2 (pt) | 2015-07-03 | 2018-09-11 | Sanofi Pasteur | vacinação concomitante contra dengue e febre amarela |
ES2937963T3 (es) * | 2015-07-21 | 2023-04-03 | Modernatx Inc | Vacunas de enfermedad infecciosa |
CA3026807A1 (fr) | 2016-06-13 | 2017-12-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Acides nucleiques codant pour des particules du type du virus zika et leur utilisation dans des vaccins contre le virus zika et des dosages de diagnostic |
US20180028643A1 (en) * | 2016-06-21 | 2018-02-01 | Brock Adam Kingstad-Bakke | Zika virus vaccines using virus-like particles |
WO2018052549A1 (fr) | 2016-09-19 | 2018-03-22 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Vaccins contre le virus zika |
EP3541416A1 (fr) * | 2016-11-17 | 2019-09-25 | GlaxoSmithKline Biologicals SA | Constructions à base d'antigènes du virus zika |
WO2018152526A1 (fr) | 2017-02-20 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Vaccins contre le virus zika |
JP7313345B2 (ja) | 2017-10-05 | 2023-07-24 | サノフィ・パスツール | デング熱に対するブースターワクチン接種のための組成物 |
US11292816B2 (en) | 2018-02-22 | 2022-04-05 | Euroimmun Medizinische Labordiagnostika Ag | Assay for the diagnosis of viral infections |
EP3530668A1 (fr) * | 2018-02-22 | 2019-08-28 | Euroimmun Medizinische Labordiagnostika AG | Nouveau dosage pour le diagnostic d'infections virales |
CN113429479B (zh) * | 2018-04-04 | 2023-03-10 | 中国科学院微生物研究所 | 一种高灵敏度的黄热病毒人源单克隆抗体及其应用 |
CN108904793B (zh) * | 2018-07-29 | 2021-03-30 | 首都医科大学附属北京友谊医院 | 预防流行性乙型脑炎的dna疫苗及其构建方法 |
US20220054620A1 (en) * | 2018-12-20 | 2022-02-24 | The Wistar Institute Of Anatomy And Biology | Vaccines against powassan virus, and methods of using same |
WO2021127580A1 (fr) * | 2019-12-18 | 2021-06-24 | Maslow Joel | Antigènes du virus powassan et compositions associées, et leurs utilisations pour vacciner et traiter des patients |
KR102216078B1 (ko) * | 2020-04-22 | 2021-02-16 | 국방과학연구소 | 유전자 백신으로 사용하기 위한 항원 유전자 전달용 발현 벡터 및 이를 포함하는 유전자 백신 |
US20230272405A1 (en) * | 2020-06-22 | 2023-08-31 | University Of Connecticut | Flavivirus signal peptides, vaccine constructs, and methods therefor |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1601438A (fr) | 1968-10-17 | 1970-08-24 | ||
JPS53133627A (en) | 1977-04-25 | 1978-11-21 | Nippon Seibutsu Kagaku Kenkiyu | High purity deactivated vaccine for japanese encephalitis |
JPH0768267B2 (ja) * | 1986-06-05 | 1995-07-26 | 財団法人阪大微生物病研究会 | フラビウイルス抗原 |
JPS634895A (ja) | 1986-06-24 | 1988-01-09 | Mitsubishi Electric Corp | オゾン精製水供給装置 |
JPS63105682A (ja) | 1986-10-23 | 1988-05-10 | Mitsubishi Kasei Corp | デングウイルス3型由来のcDNA |
FR2614219B1 (fr) | 1987-04-23 | 1993-07-09 | Materiels Annexes Dialyse | Procede de fabrication de granules destines a la preparation de solutions de dialyse et installation pour sa mise en oeuvre. |
JPH084508B2 (ja) | 1987-09-16 | 1996-01-24 | 国立予防衛生研究所長 | 組み換えワクチニアウイルス |
US4783502A (en) | 1987-12-03 | 1988-11-08 | Ppg Industries, Inc. | Stable nonaqueous polyurethane microparticle dispersion |
JP2511494B2 (ja) | 1988-05-12 | 1996-06-26 | 善治 松浦 | 日本脳炎ウイルス表面抗原蛋白質の製造法 |
IL91304A0 (en) | 1988-08-20 | 1990-03-19 | Us Health | Recombinant vaccinia virus for prevention of disease caused by flavivirus |
JPH0425408A (ja) | 1990-05-21 | 1992-01-29 | Hitachi Ltd | ペレタイジングシステムの自動連続運転制御方法 |
FR2665710A1 (fr) | 1990-08-10 | 1992-02-14 | Pasteur Institut | Baculovirus recombinant exprimant les proteines e et ns1 de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae, applications diagnostiques et therapeutiques. |
US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5494671A (en) | 1990-08-27 | 1996-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | C-terminally truncated dengue and Japanese encephalitis virus envelope proteins |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
ES2153223T3 (es) * | 1991-09-19 | 2001-02-16 | Us Health | Flavivirus quimericos y/o flavivirus de crecimiento restringido. |
JPH05276941A (ja) | 1992-02-28 | 1993-10-26 | Nippon Zeon Co Ltd | フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法 |
JPH07265093A (ja) | 1994-03-30 | 1995-10-17 | Chemo Sero Therapeut Res Inst | 哺乳動物細胞を用いる日本脳炎ウイルス表面抗原蛋白質の製法 |
ATE227584T1 (de) | 1995-05-24 | 2002-11-15 | Hawaii Biotech Group | Untereinheitsimpfstoff gegen flavivirus infektion |
US6136561A (en) * | 1995-05-24 | 2000-10-24 | Hawaii Biotechnology Group, Inc. | Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems |
US6074865A (en) * | 1995-07-20 | 2000-06-13 | The United States Of America As Represented By The Secretary Of The Army | Recombinant dengue virus DNA fragment |
US6455509B1 (en) * | 1996-06-04 | 2002-09-24 | The United States Of America As Represented By The Secretary Of The Navy | Dengue nucleic acid vaccines that induce neutralizing antibodies |
US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
CA2282790C (fr) | 1997-02-28 | 2011-04-19 | Oravax, Inc. | Vaccins chimeres a base de flavivirus |
DE69834041T2 (de) | 1997-07-31 | 2006-12-14 | Hawaii Biotech, Inc., Aiea | Rekombinante dimerische hüllproteine als impfstoff gegen eine flavivirale infektion |
WO1999026653A1 (fr) | 1997-11-20 | 1999-06-03 | United States Army Medical Research And Material Command | Vaccins a base d'adn diriges contre les flavivirus transmis par les tiques |
IL139844A0 (en) | 1998-06-04 | 2002-02-10 | Us Gov Health & Human Serv | Nucleic acid vaccines for prevention of flavivirus infection |
US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
US20050048073A1 (en) | 2001-02-28 | 2005-03-03 | De Groot Anne S. | Methods of determining west nile virus epitopes and method of using the same |
WO2002072036A2 (fr) | 2001-03-12 | 2002-09-19 | Yale University | Procedes et compositions comprenant des polypeptides du virus west nile |
-
2001
- 2001-04-04 US US09/826,115 patent/US7227011B2/en not_active Expired - Lifetime
-
2002
- 2002-04-04 CA CA2443323A patent/CA2443323C/fr not_active Expired - Lifetime
- 2002-04-04 BR BRPI0208301 patent/BRPI0208301B8/pt not_active IP Right Cessation
- 2002-04-04 EP EP02763960A patent/EP1383931A4/fr not_active Withdrawn
- 2002-04-04 EP EP10177282.0A patent/EP2332572B1/fr not_active Expired - Lifetime
- 2002-04-04 US US10/500,796 patent/US7662394B2/en not_active Expired - Lifetime
- 2002-04-04 CN CNB02807758XA patent/CN1304575C/zh not_active Expired - Lifetime
- 2002-04-04 EP EP08004141A patent/EP1935991B1/fr not_active Expired - Lifetime
- 2002-04-04 JP JP2002579516A patent/JP4448281B2/ja not_active Expired - Lifetime
- 2002-04-04 KR KR1020037013021A patent/KR100913984B1/ko active IP Right Grant
- 2002-04-04 MX MXPA03008838A patent/MXPA03008838A/es active IP Right Grant
- 2002-04-04 CN CNA2007100020999A patent/CN101002936A/zh active Pending
- 2002-04-04 WO PCT/US2002/010764 patent/WO2002081754A1/fr active IP Right Grant
- 2002-04-04 NZ NZ529106A patent/NZ529106A/en not_active IP Right Cessation
-
2003
- 2003-09-29 ZA ZA2003/07580A patent/ZA200307580B/en unknown
-
2004
- 2004-08-02 HK HK04105654A patent/HK1062836A1/xx not_active IP Right Cessation
-
2006
- 2006-06-14 US US11/424,138 patent/US7632510B2/en not_active Expired - Lifetime
- 2006-06-14 US US11/424,127 patent/US7521177B2/en not_active Expired - Fee Related
-
2009
- 2009-07-24 US US12/508,946 patent/US8232379B2/en not_active Expired - Fee Related
- 2009-08-21 JP JP2009192598A patent/JP5236597B2/ja not_active Expired - Fee Related
- 2009-10-15 US US12/580,080 patent/US8221768B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1062836A1 (en) | Nucleic acid vaccines for prevention of flavivirusinfection | |
GB0118959D0 (en) | Nucleic acid amplification method | |
AU2002336760A8 (en) | Mutable vaccines | |
HUP0402471A3 (en) | Vaccine | |
HUP0402259A3 (en) | Vaccines | |
IL139844A0 (en) | Nucleic acid vaccines for prevention of flavivirus infection | |
HUP0303372A3 (en) | Vaccine | |
GB0306611D0 (en) | Novel vaccine | |
GB0121171D0 (en) | Vaccine | |
AU2002353310A8 (en) | Method for the preparation of nucleic acids | |
EP1418949A4 (fr) | Inhibiteur de methylation d'adn | |
PL364901A1 (en) | Oxalic acid derivatives | |
EP1446488A4 (fr) | Systeme d'expression d'acide nucleique regule | |
AU2002366435A8 (en) | Nucleic acid amplification | |
HUP0203848A3 (en) | Nucleic acid vaccination | |
IL158004A0 (en) | Method of enhancing entomophilous | |
EP1461427A4 (fr) | Procedes d'expression ciblee d'un acide nucleique therapeutique | |
AU2002327959A1 (en) | Adjuvants for nucleic acid vaccines | |
GB0105238D0 (en) | Vaccines | |
AU2002347346A8 (en) | Dna vaccine | |
GB0100785D0 (en) | Nucleic acid vaccine | |
GB0125865D0 (en) | Isolation of nucleic acid | |
GB0125862D0 (en) | Nucleic acid modification | |
GB0125868D0 (en) | Nucleic acid modification | |
GB0118475D0 (en) | Dna vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20220403 |